Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer

Propanc Biopharma, Inc. announced that PRP suppressed the TGF-β pathway and the tumor microenvironment in pancreatic cancer, elucidated by one of the Company’s joint researchers, Mrs. Belén Toledo Cutillas MSc, at the laboratory of Professor Macarena Perán, PhD, University of Jaén, Granada, Spain.